SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two is drawing attention from the GTA VI extended gameplay preview and its expected blockbuster launch, with traders citing strong audience interest and potential long-term online monetization. Sentiment is largely bullish, but debate centers on whether the hype is already priced in and whether leaked footage, performance concerns, or further delays could trigger volatility.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Rotation from high-beta technology and semiconductor stocks into value, defensive, dividend-paying equities has lifted SCHDs profile, with traders highlighting its relative strength, new highs, and role as a portfolio stabilizer. The community remains broadly constructive and continues buying or dollar-cost averaging, although some investors caution that the strong run has compressed the yield and may invite profit-taking or a pullback.

Photronics, Inc. engages in the provision of photomasks, which are quartz or glass plates containing microscopic images of electronic circuits for use in the fabrication of integrated circuits and flat-panel displays. The company was founded by Constantine S. Macricostas in 1969 and is headquartered in Brookfield, CT.

Photronics, Inc.

A quarterly earnings release and forward outlook are driving attention: traders note results that exceeded expectations, yet the shares have suffered a sharp post-earnings reversal amid debate over near-term visibility and execution. Bulls view the selloff as an overreaction and cite Photronics cash-rich balance sheet and AI-related photomask exposure, while bears remain concerned about softer demand and further downside.

$4CHAN is a meme token on the Ethereum Network.   4ChanToken represents a global crypto community that pays homage to the memetic powerhouses of the internet as Pepe, Doge, Shib and all major memes inventor combining them all into one super meme token that is $4CHAN. At its core, 4ChanToken embodies the untamed spirit of the notorious 4chan imageboard, where iconic memes are born, nurtured, and unleashed upon the world. With an unyielding spirit of irreverence and a touch of mischief, $4CHAN has emerged as the darling of meme enthusiasts, internet dwellers, and crypto aficionados alike.   The foundation of 4ChanToken lies in its community. We’ve harnessed the chaotic energy of this digital realm to create a currency that celebrates the power of memetic expression, empowering users to engage in a truly unique and decentralized economy. As a passionate supporter, you’ll join a vibrant ecosystem where dank memes and viral sensations are the lifeblood of commerce. 4ChanToken is more than just a digital currency – it’s the place where memes are born.  The ultimate playground for memelords and crypto degens. Based on the simplicity of holdrs/volume operating a store of value.  The identification of this value is best described as 'digital gold'. That $4chan can ultimately represent a superior store of value relative to all other forms of memecoins by embodying all memes in one token as the factual birthplace of all popular memes.

4Chan

Attention is centered on 4CHANs apparent outperformance of major cryptocurrencies and other meme coins, alongside promotion of its Ethereum-based, 4chan-themed community and large token supply. Supporters are urging accumulation and long-term holding, while skeptics continue to characterize the move as a speculative pump-and-dump.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Anticipation of ERCOTs Batch Zero conditional classifications for Ciphers Texas large-load projects is the dominant catalyst, with traders focused on whether roughly 2 GW of proposed capacity clears the states power-interconnection review. The community is broadly optimistic that stricter screening could benefit Ciphers established AI/HPC infrastructure pipeline, though the outcome remains uncertain and the stocks sharp volatility and broader data-center selloff have fueled significant bearish debate.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma's $230M Dutch auction tender offer to retire up to ~23% of shares at $5$5.75 is the core catalyst, with the community debating whether to tender or hold for further litigation upside from Moderna/Pfizer settlements and a fast-tracked HBV program.

Anthropic

Anthropics confidential SEC filing and preparations for a potential mega-IPO are driving attention, alongside its rapid Claude adoption and rising private-market valuation. Traders are split between viewing the listing as a major AI opportunity and warning that lofty expectations, heavy infrastructure spending, and competition could make the shares vulnerable after going public.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Record-high refining margins and tight global fuel supplies tied to geopolitical disruptions are driving attention to Valero, with traders also focused on potential access to Venezuelan heavy crude that suits its Gulf Coast refineries. The community is broadly bullish on the refining thesis and recent highs, though some traders argue the stock is overbought and vulnerable to a pullback or weaker margins.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compounds DAO-approved shift toward institutional finance, alongside new leadership from crypto custody firms, is driving renewed attention around a potential institutional pivot. Traders are divided between those viewing the capped supply and strategic reset as bullish and skeptics citing weak price action, competition from Aave, and liquidity or security concerns.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

An abrupt CEO departure and broader leadership changes have driven volatility, raising questions about Legend Biotechs strategy and its relationship with J&J and GenScript. Traders remain divided between concerns over governance, competition and China-related risk, and optimism that strong CARVYKTI growth plus promising in-vivo CAR-T data could support a strategic deal or rerating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?

DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Guggenheim Reiterates Buy Rating for DBV Technologies (NASDAQ:DBVT)

Guggenheim reiterated a "buy" rating and issued a $51.00 target price on shares of DBV Technologies in a research report on Monday...

What is HC Wainwright's Estimate for DBVT FY2029 Earnings?

DBV Technologies S.A. (NASDAQ:DBVT - Free Report) - Equities research analysts at HC Wainwright decreased their FY2029 earnings estimates for shares of DBV Technologies in a research note issued on Friday, May 1st. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of $0...

DBV Technologies (NASDAQ:DBVT) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of DBV Technologies from a 'sell' rating to a 'hold' rating in a research note on Saturday...

DBV Technologies (NASDAQ:DBVT) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Citizens Jmp boosted their price target on DBV Technologies from $47.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday...

DBV Technologies (NASDAQ:DBVT) Posts Quarterly Earnings Results, Misses Estimates By $0.41 EPS

DBV Technologies (NASDAQ:DBVT - Get Free Report) posted its earnings results on Thursday. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of...

Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?

Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and DBV Technologies S.A. (DBVT) have performed compared to their sector so far this year.

DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nine ratings firms that are covering the firm, Marketbeat Ratings reports...

DBV Technologies (DBVT) to Release Quarterly Earnings on Wednesday

DBV Technologies (NASDAQ:DBVT) will be releasing its Q4 2025 earnings before the market opens on Wednesday, April 29. (View Earnings Report at...

DBV Technologies (NASDAQ:DBVT) Shares Pass Above Fifty Day Moving Average   - Time to Sell?

DBV Technologies (NASDAQ:DBVT) Stock Crosses Above 50 Day Moving Average - Should You Sell...

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.

DBV Technologies - ADR

DBV Technologies Stock Soars 63% After Hours As Strong Results For Peanut Allergy Patch Clears Path For FDA Filing

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$13.54
Prev Close	$14.41
Open	$14.38
Dividend Yield	0.00%
50-Day Moving Average	$14.81
Beta	0.50
Avg. Volume	292,624.84
PE Ratio	-3.85

52-Week High	$26.19
52-Week Low	$8.70
Market Capitalization	$850.93M
EPS (Annual)	-$5.28
Price to Book	5.00
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info